Protein kinase A antagonist inhibits β-catenin nuclear translocation, c-Myc and COX-2 expression and tumor promotion in ApcMin/+ mice

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Brudvik, Kristoffer W ^a   Paulsen, Jan E ^b   Aandahl, Einar M ^a,c   Roald, Borghild ^d   Taskén, Kjetil ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apcmin + b catenin; Colorectal cancer; Cox 2; Protein kinase a

Indexed keywords

APC PROTEIN; BETA CATENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLOOXYGENASE 2; MYC PROTEIN; PROSTAGLANDIN E2;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINAL ADENOMA; INTESTINE CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ACTIVE TRANSPORT, CELL NUCLEUS; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; DOWN-REGULATION; HCT116 CELLS; HUMANS; MICE; PROTO-ONCOGENE PROTEINS C-MYC; THIONUCLEOTIDES;

ANIMALIA; MUS;

EID: 83455169214     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-149     Document Type: Article

References (30)

1. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis 2009, 4:22. 10.1186/1750-1172-4-22, 2772987, 19822006.
2. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 1996, 272:1023-1026. 10.1126/science.272.5264.1023, 8638126.
3. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997, 16:3797-3804. 10.1093/emboj/16.13.3797, 1170003, 9233789.
4. Städeli R, Hoffmans R, Basler K. Transcription under the Control of Nuclear Arm/[beta]-Catenin. Current Biology 2006, 16:R378-R385. 10.1016/j.cub.2006.04.019, 16713950.
5. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive Transcriptional Activation by a b-Catenin-Tcf Complex in APC-/- Colon Carcinoma. Science 1997, 275:1784-1787. 10.1126/science.275.5307.1784, 9065401.
6. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a Target of the APC Pathway. Science 1998, 281:1509-1512.
7. Tetsu O, McCormick F. [beta]-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422-426. 10.1038/18884, 10201372.
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
9. Kraus S, Arber N. Cancer: Do aspirin and other NSAIDs protect against colorectal cancer?. Nat Rev Gastroenterol Hepatol 2011, 8:125-126. 10.1038/nrgastro.2010.217, 21243014.
10. Psaty BM, Potter JD. Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas. New England Journal of Medicine 2006, 355:950-952. 10.1056/NEJMe068158, 16943408.
11. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA, Tasken K. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008, 57:813-821. 10.1007/s00262-007-0417-x, 17962941.
12. Fujino H, Toyomura K, Chen X, Regan JW, Murayama T. Prostaglandin E2 regulates cellular migration via induction of vascular endothelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochemical Pharmacology 2011, 81:379-387. 10.1016/j.bcp.2010.11.001, 21070749.
13. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001, 276:18075-18081. 10.1074/jbc.M009689200, 11278548.
14. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-3340. 10.1073/pnas.94.7.3336, 20370, 9096394.
15. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc[Delta]716 knockout mice. Nat Med 2001, 7:1048-1051. 10.1038/nm0901-1048, 11533709.
16. Taurin S, Sandbo N, Qin Y, Browning D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006, 281:9971-9976. 10.1074/jbc.M508778200, 16476742.
17. Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol 2005, 25:9063-9072. 10.1128/MCB.25.20.9063-9072.2005, 1265785, 16199882.
18. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT, et al. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 2009, 136:1136-1147. 10.1016/j.cell.2009.01.015, 2692708, 19303855.
19. Buchanan FG, DuBois RN. Connecting COX-2 and Wnt in cancer. Cancer Cell 2006, 9:6-8. 10.1016/j.ccr.2005.12.029, 16413466.
20. Chiu CH, McEntee MF, Whelan J. Discordant effect of aspirin and indomethacin on intestinal tumor burden inApcMin/+ mice. Prostaglandins, Leukotrienes and Essential Fatty Acids 2000, 62:269-275.
21. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
22. Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol 2006, 16:73-79. 10.1016/j.semcancer.2005.07.009, 16140545.
23. Kettunen HL, Kettunen AS, Rautonen NE. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 2003, 63:5136-5142.
24. Wang HM, Zhang GY. Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 2005, 11:340-343.
25. Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 2003, 8:649-654.
26. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510. 10.1126/science.1116221, 16293724.
27. Andrei M, Bjornstad V, Langli G, Romming C, Klaveness J, Tasken K, Undheim K. Stereoselective preparation of (RP)-8-hetaryladenosine-3[prime or minute],5[prime or minute]-cyclic phosphorothioic acids. Org Biomol Chem 2007, 5:2070-2080. 10.1039/b702403g, 17581650.
28. Nayjib B, Zeddou M, Drion P, Boniver J, Tasken K, Rahmouni S, Moutschen M. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice. Open Immunol J 2008, 20-24.
29. Koch T, Petro A, Darrabie M, Opara E. Effects of Esomeprazole Magnesium on Nonsteroidal Anti-Inflammatory Drug Gastropathy. Digestive Diseases and Sciences 2005, 50:86-93. 10.1007/s10620-005-1283-z, 15712643.
30. Paulsen JE, Steffensen IL, Andreassen A, Vikse R, Alexander J. Neonatal exposure to the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. Carcinogenesis 1999, 20:1277-1282. 10.1093/carcin/20.7.1277, 10383901.